6 June 2017

Prof. Ton de Boer new President of the Dutch Medicines Evaluation Board

Ton de Boer
Prof. Ton de Boer, Utrecht University

As of 1 August 2017, Ton de Boer, Professor of  Pharmacotherapy at Utrecht University, will be appointed as the new Chairman of the Medicines Evaluation Board (MEB) of the Netherlands. De Boer is a physician, clinical pharmacologist and epidemiologist. He will continue working as a part-time Professor at Utrecht University in addition to his duties as Chairman of the Board. The Minister of Health, Welfare and Sport has appointed him to be the successor of the current Chairman, Prof. Bert Leufkens, who held the position for the last ten years.

MEB Secretary and Director Hugo Hurts: “With Ton de Boer, the  Medicines Evaluation Board will gain a multifaceted Chairmant with a broad network in the national pharmaceutical chain. With his scientific expertise, he will be able to create a link with the practical application of pharmaceuticals. We believe that in De Boer we have found a worthy successor to Prof. Leufkens.”

Trust

Ton de Boer: “Patients should be able to trust their medications. That is what the MEB works to achieve every day, through the evaluation and monitoring of the medications’ effectiveness, risks and quality. It is an honour to join a group of extremely knowledgeable and driven colleagues to contribute to this goal as the Chairman of the Board.”

Ton de Boer

De Boer (1955) began his career as an Internal Medicine resident, and earned his PhD in the field of Clinical Pharmacology. After a variety of research and teaching positions in Leiden and later Utrecht, in 2001 he was appointed as Professor of  Pharmacotherapy, and as Educational Director of the Pharmaceutical Sciences study programme at Utrecht University. From 2007 to September 2015, he served as Head of the Department of Pharmaceutical Sciences.

Medicines Evaluation Board

The Board is legally restricted to a maximum of 17 members, each with a broad scientific, clinical and patient network in the Netherlands. The Board makes decisions regarding the admission of pharmaceuticals to the Dutch market, and is responsible for the constant monitoring of all pharmaceuticals currently available in that market. The MEB is part of a European network of pharmaceutical authorities. The Chairman and members of the Board are appointed by the Minister of Health, Welfare and Sport for a term of four years, and may be re-appointed to a maximum of two terms.